ClinicalTrials.gov
ClinicalTrials.gov Menu

Studies of the Immune Response to Vaccination After Hematopoietic Stem Cell Transplantation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01581164
Recruitment Status : Completed
First Posted : April 20, 2012
Last Update Posted : May 8, 2015
Sponsor:
Information provided by (Responsible Party):
University of California, San Francisco

April 16, 2012
April 20, 2012
May 8, 2015
December 2011
December 2014   (Final data collection date for primary outcome measure)
Change from baseline of Immune response at Day 90 post vaccination. [ Time Frame: Participants will have blood drawn at baseline and on Days 1, 7, 10, 28, and 90 post vaccinations following hematopoietic stem cell transplantation. Average study participation is 1-3 years post transplant. ]
Participants will have blood drawn at baseline to Day 90 post vaccinations following hematopoietic stem cell transplantation. Average study participation is 1-3 years post transplant.
Same as current
Complete list of historical versions of study NCT01581164 on ClinicalTrials.gov Archive Site
  • Immune response [ Time Frame: Participants will have blood drawn at 1 month intervals post hematopoietic stem cell transplantation . Average study participation is 1-3 years post transplant. ]
  • Immune response [ Time Frame: Blood will drawn at baseline and Days 1, 7, 10, 28, and 90 post vaccination. Participants will receive the vaccine, 12-28 months post hematopoietic stem cell transplantation. ]
Same as current
Not Provided
Not Provided
 
Studies of the Immune Response to Vaccination After Hematopoietic Stem Cell Transplantation
Studies of the Immune Response to Vaccination After Hematopoietic Stem Cell Transplantation
The purpose of this research study is to perform a serial analysis of immune function using blood cells and sera obtained from patients after vaccination following hematopoietic stem cell transplantation (HSCT). The focus of this study will be to characterize several immune parameters during the clinical course of HSCT and correlate these findings with the effect of vaccination.

Hematopoietic stem cell transplantation therapy is potentially curative for many malignant and non-malignant hematopoietic disorders. Disease recurrence and infection remain major causes of morbidity and mortality following HSCT. While innate immunity (myeloid and NK cell) is restored relatively quickly following HSCT, a prolonged period of lymphopenia occurs in all patients. This delay in lymphoid reconstitution is exacerbated with age and results in severely dampened adaptive immune responses. In children who have received chemotherapy and HSCT, T cell function generally recovers within 6 to twelve months. In contrast, lymphoid deficiency in adults may require years, and often never recovers to pre-transplant levels. Much of the delay in lymphocyte recovery is thought to be due to decreased thymic T cell production and export and the resulting expansion of treatment resistant T cell clones. Peripheral expansion of T cells in a lymphopenic setting leads to a narrowing of the TCR repertoire and manifests as a decrease in the magnitude of response to new antigens.

These long-lasting T cell deficiencies have been shown to play a direct role in post-transplant complications. There are many studies that correlate decreased T cell number and function (specifically CD4+ T cells) with an increase in post-transplant infections and relapse has been shown to be inversely proportional to T cell reconstitution following both autologous and allogeneic HSCT. Furthermore, this prolonged deficit in T cell function decreases the effectiveness of vaccination against tumour antigens and infectious diseases as well as other post-transplant immunotherapeutic strategies. Following HSCT, patients lose immunological memory not only to infectious microorganisms to which they were previously exposed but also bacterial and viral vaccines given prior to the HSCT , increasing the chance of infection post-transplant. Primary immunization requires antigenic stimulation and functionally mature T cells and therefore at least partial reconstitution of the T and B cell pools is necessary before successful reimmunization can occur.

This study presents an opportunity to analyze, at a systems level, the responses to vaccination in patients who are treated with HSCT. The expected high frequency of low responders to vaccination will permit comparisons of gene expression and immune cell activation between high and low responders as measured by the rate of seroconversion and HAI titers. The evaluation of live VZV vaccination is essential for these objective as the investigators hypothesize that live vaccination will induce a more specific immune response than dead (ie: influenza) vaccination. This study may also generate novel hypotheses about the mechanistic basis for reduced responses to vaccines post HSCT.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:
Serum will be collected and stored for immunologic analysis after vaccination. Samples will be cryopreserved. No cell lines will be created using samples procured on this protocol.
Non-Probability Sample
Patients who have been treated with HSCT
Hematopoietic Stem Cell Transplant
  • Biological: Influenza vaccine
    Influenza vaccine: Injection, post transplant
    Other Name: flu vaccine
  • Biological: Varicella vaccine
    Varicella vaccine: Injection, post transplant
    Other Name: chicken pox vaccine
HSCT patients
Patients who have been treated with HSCT
Interventions:
  • Biological: Influenza vaccine
  • Biological: Varicella vaccine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
12
90
December 2014
December 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients who have been treated with HSCT.
  • Patients must be 5-70 years of age.
  • For patients participating in Objective 3: Patients must be immunocompetent (no active GVHD and must be off all immunosuppression)

Exclusion Criteria:

  • Patients who do not wish to participate or unable to provide the necessary blood samples required for the protocol.
  • Patients with history of allergic reaction to a vaccination.
  • Patient has had Guillain-Barre syndrome.
  • Patients who are pregnant or become pregnant.
Sexes Eligible for Study: All
5 Years to 70 Years   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01581164
UCSF Protocol No. 112526
Yes
Not Provided
Not Provided
University of California, San Francisco
University of California, San Francisco
Not Provided
Principal Investigator: Jeffrey Venstrom, MD University of California, San Francisco
University of California, San Francisco
May 2015